Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration

Overview

The purpose of this study is to determine the efficacy, safety and tolerability of multiple doses of RN6G in subjects with Geographic Atrophy Secondary to Age-related Macular Degeneration.

Full Title of Study: “A Phase 2 Multi-center, Randomized, Double-masked, Placebo-controlled, Multi-dose Study To Investigate The Efficacy, Safety, Pharmacokinetics And Pharmacodynamics Of Rn6g (Pf-04382923) In Subjects With Geographic Atrophy Secondary To Age-related Macular Degeneration”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: September 2013

Detailed Description

The trial was terminated early on April 12, 2013 due to an organizational decision, which was not based on safety or efficacy concerns. Subjects who were already enrolled into the study were followed.

Interventions

  • Biological: RN6G
    • Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
  • Biological: Placebo
    • Intravenous, 11 doses, 30 minute infusion

Arms, Groups and Cohorts

  • Experimental: PF-04382923
  • Placebo Comparator: Placebo

Clinical Trial Outcome Measures

Primary Measures

  • Mean Reduction (in Study Eye) in Rate of Growth of Geographic Atrophy (GA) at Day 309
    • Time Frame: Baseline and Day 309
    • GA is the advanced form of dry age-related macular degeneration (AMD). The reduction in GA area of the study eye was based on Fundus Autofluorescence (FAF) at 30 days post last dose administration (Day 309).
  • Mean Reduction (in Study Eye) in Rate of Growth of GA at Day 449 (End of Study)
    • Time Frame: Baseline and Day 449
    • GA is the advanced form of dry AMD. The reduction in GA area in the study eye was based on FAF at end of study (Day 449).

Secondary Measures

  • Mean Best Corrected Visual Acuity (BCVA) at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
  • Percentage Change From Baseline in BCVA Correct Number of Letters at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • BCVA is measured using an eye chart and is reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity).
  • Percentage Change From Baseline in BCVA Correct Number of Lines at Months 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • BCVA is measured using an eye chart and is reported as the number of lines read correctly in the study eye. The lower the number of lines read correctly on the eye chart, the worse the vision (or visual acuity).
  • Mean Low Luminance Best Corrected Visual Acuity (LL-BCVA) at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • LL-BCVA is the measure of visual acuity under low light conditions.
  • Percentage Change From Baseline in LL-BCVA Correct Number of Letters at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • LL-BCVA is the measure of visual acuity under low light conditions.
  • Percentage Change From Baseline in LL-BCVA Correct Number of Lines at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • LL-BCVA is the measure of visual acuity under low light conditions.
  • Change From Baseline in Contrast Sensitivity at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Contrast sensitivity was measured using the Pelli-Robson chart at 1 meter. Participants were tested for contrast sensitivity using +0.50 addition over the protocol refraction providing the best-corrected distance VA. Contrast sensitivity was recorded as the log of the faintest triplet for which 2 of the 3 letters were read correctly.
  • Percentage Change From Baseline in Contrast Sensitivity at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Contrast sensitivity was measured using the Pelli-Robson chart at 1 meter. Subjects were tested for contrast sensitivity using +0.50 addition over the protocol refraction providing the best-corrected distance VA. Contrast sensitivity was recorded as the log of the faintest triplet for which 2 of the 3 letters were read correctly.
  • Change From Baseline in Reading Speed at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading speed in the study eye was assessed using modified Bailey-Lovie word charts. Participants read the chart for 2 minutes and the number of words read correctly per minute was totaled. An increase in the number of words read correctly indicated an improvement and a decrease in the number of words read correctly indicated a worsening.
  • Change From Placebo in Reading Speed at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading speed in the study eye was assessed using modified Bailey-Lovie word charts. Participants read the chart for 2 minutes and the number of words read correctly per minute was totaled. An increase in the number of words read correctly indicated an improvement and a decrease in the number of words read correctly indicated a worsening.
  • Percentage Change From Baseline in Reading Speed at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading speed in the study eye was assessed using modified Bailey-Lovie word charts. Participants read the chart for 2 minutes and the number of words read correctly per minute was totaled. An increase in the number of words read correctly indicated an improvement and a decrease in the number of words read correctly indicated a worsening.
  • Change From Baseline in Reading Acuity at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading Acuity was measured using the Radner reading charts and expressed in terms of logRAD (logrithmic Reading Acuity Determination).
  • Change From Placebo in Reading Acuity at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading Acuity was measured using the Radner reading charts and expressed in terms of logRAD.
  • Percentage Change From Baseline in Reading Acuity at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • Reading Acuity was measured using the Radner reading charts and expressed in terms of logRAD.
  • Change From Baseline in Critical Print Size Reading at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • The critical print size is the smallest print size at which participants can read with their maximum reading speed.
  • Change From Placebo in Critical Print Size Reading at 9, 12, 15 Months and End of Study
    • Time Frame: Baseline, Month 9, Month 12, Month 15, and End of Study
    • The critical print size is the smallest print size at which participants can read with their maximum reading speed.
  • Number of Participants With Treatment-Emergent Laboratory Abnormalities
    • Time Frame: Day 85 and Day 169
    • Laboratory assessments include: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein); coagulation assessments.
  • Number of Participants With Abnormal Change From Baseline in Vital Signs
    • Time Frame: Screening, Days 28, 57, 85, 113, 141, and 169
    • Vital sign assessments include: supine systolic and diastolic blood pressure, pulse rate and body temperature.
  • Number of Participants With Clinically Significant Treatment-Emergent Electrocardiogram (ECG) Findings
    • Time Frame: Days 28, 57, 85, 113 and 169
    • Clinically significant ECG findings include: corrected QT (QTc) > 450 msec, QTc >500 msec, change in QTc between 30 and 60 msec, change in QTc greater than or equal to 60 msec.
  • Number of Participants With Positive Anti-Drug Antibody (ADA)
    • Time Frame: Day 57 and Day 169
    • The number of participants with positive ADA was to be summarized for each treatment arm.
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) According to Seriousness
    • Time Frame: Days 28, 57, 85, 113, 141 and 169
    • An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Seriousness of an AE was assessed under the criteria of serious adverse event (SAE). An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
  • Number of Participants With Treatment-Related TEAEs
    • Time Frame: Days 28, 57, 85, 113, 141 and 169
    • An AE was an untoward medical occurrence in a participant who received study drug without regard to causal relationship. An investigator’s relationship assessment is the determination of whether there exists a reasonable possibility that the investigational product caused or contributed to an AE.
  • Maximum Observed Plasma Concentration (Cmax)
    • Time Frame: Days 1, 28,57, 85, 169, 253, 281, 309, 337, and 449
  • Minimum Observed Plasma Trough Concentration (Cmin)
    • Time Frame: Days 1, 28,57, 85, 169, 253, 281, 309, 337, and 449
  • Area Under the Concentration-Time Curve From Time Zero Until Last Sampling Time (AUCt)
    • Time Frame: Days 1, 28,57, 85, 169, 253, 281, 309, 337, and 449
  • Clearance at Steady State (CLss)
    • Time Frame: Days 1, 28,57, 85, 169, 253, 281, 309, 337, and 449
    • Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of study drug (R0/Css)
  • Accumulation Ratio (Rac) for AUCt
    • Time Frame: Days 1, 28,57, 85, 169, 253, 281, 309, 337, and 449
  • Plasma Population PK Parameters
    • Time Frame: Days 1, 28, 57, 85, 169, 253, 281, 309, 337 and 449
    • Population PK parameters were to be evaluated for Cmax, AUCt, Cmin, CLss, and Rac for AUCt between the first and last (11th) doses.
  • Change From Baseline in Total Amyloid Beta (A-Beta) 1-x Plasma Concentration at End of Study (Day 449)
    • Time Frame: Baseline, Day 449
    • Concentration of total amino acid peptide, known as A-Beta 1-x, in plasma.
  • Change From Baseline in Amyloid Beta (A-Beta) 1-40 Plasma Concentration at End of Study (Day 449)
    • Time Frame: Baseline, Day 449
    • Concentration of amino acid peptide, known as A-Beta 1-40, in plasma.
  • Change From Baseline in Amyloid Beta (A-Beta) 1-42 Plasma Concentration at End of Study (Day 449)
    • Time Frame: Baseline, Day 449
    • Concentration of amino acid peptide, known as A-Beta 1-42, in plasma.

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women between the ages of 60 and 90 years.
  • Diagnosis of a geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration.
  • Best Corrected Visual Acuity (BCVA) of 20/80 or better in the study eye

Exclusion Criteria

  • Evidence of ocular disease other than geographic atrophy (GA) secondary to dry Age-Related Macular Degeneration in the study eye.
  • History or diagnosis of exudative (wet) Age-Related Macular Degeneration, with subretinal or choroidal neovascular lesions in the study eye.
  • Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous, immune, or gastrointestinal system

Gender Eligibility: All

Minimum Age: 60 Years

Maximum Age: 90 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.